Basic information
- CAS
94749-08-3- Standard SMILES
O=C(O)c1ccc2ccccc2c1O.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O- InChIKey
XTZNCVSCVHTPAI-UHFFFAOYSA-N- Molecular formula
- C36H45NO7
- Average molar mass
- 603.7 g/mol
- Monoisotopic mass
- 603.31960277
Overview
Salmeterol xinafoate is a naphthoic acid.
Names & identifiers
- Preferred name
- Salmeterol Xinafoate
- IUPAC
- 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol;1-hydroxynaphthalene-2-carboxylic acid
- English name
- Salmeterol xinafoate
- Molecular formula
- C36H45NO7
- Molecular weight
- 603.74
Names & synonyms
salmeterol xinafoate94749-08-3Serevent diskusSalmeterol 1-hydroxy-2-naphthoateGR 33343 GDTXSID1045798Xinafoate, Salmeterol6EW8Q962A5GR-33343 GADVAIR COMPONENT SALMETEROL XINAFOATEDTXCID9025798AIRDUO RESPICLICK COMPONENT SALMETEROL XINAFOATE
Show more names
1-Hydroxy-2-naphthoateSalmeterol hydroxynaphthoateSereventSalmeterol Xinafoate (1609603)ArialSN 408SiduomiGR 3343GGR-33343GSalmetedur
RefChem:56524AsmeroleBetamicanDilamax4-(1-Hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol;1-hydroxynaphthalene-2-carboxylic acidMFCD00897708Salmeterol (xinafoate)
Database identifiers
- CAS
94749-08-3
Properties
Computed structural properties
- Topological polar surface area
- 139 Ų
- Hydrogen bond donors
- 6
- Hydrogen bond acceptors
- 8
- Rotatable bonds
- 17
- Heavy atoms
- 44
- Formal charge
- 0
- Complexity
- 629
Experimental & physicochemical properties
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physicochemical properties
- Melting point
- 137 · 137-138°C
- storage temp.
- 2 · 2-8°C
- solubility
- 2 O: · H2O: slightly soluble
- form
- solid
- color
- white
- Merck
- 14 · 14,8337
- Major Application
- pharmaceutical (small molecule)
- InChIKey
- XTZNCVSCVHTPAI-UHFFFAOYSA-N
- SMILES
- C12C=CC=CC=1C(O)=C(C(=O)O)C=C2.C1(C(O)CNCCCCCCOCCCCC2C=CC=CC=2)=CC=C(O)C(CO)=C1
- CAS DataBase Reference
- 94749 · 94749-08-3(CAS DataBase Reference)
- FDA UNII
- 6 EW8Q962A5 · 6EW8Q962A5
- UNSPSC Code
- 41116107 · 41116107
- NACRES
- 24 · NA.24
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
This chemical does not meet GHS hazard criteria for 72.2% (52 of 72) of all reports.
Danger
H318 (15.3%): Causes serious eye damage [Danger Serious eye damage/eye irritation]
P203, P264+P265, P273, P280, P305+P351+P338, P305+P354+P338, P317, P318, P337+P317, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 72 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard information
Hazard Classes and CategoriesEye Dam. 1 (15.3%)
Safety data
- wgk
- 3
- rtecs
- QJ1970500
- hs_code
- 2922504500
- risk_code
- 36/37/38
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- hazard_code
- Xi
- safety_code
- 22-24/25-36-26
- Storage Class
- 11 - Combustible Solids
- Hazard statements
- H315-H319-H335
- Precautionary statements
- P280-P271
Chemistry & industry
Pharmacology
FDA Pharmacological Classification
SALMETEROL XINAFOATE
beta2-Adrenergic Agonist [EPC]; Adrenergic beta2-Agonists [MoA]
MeSH Pharmacological Classification
Agents that cause an increase in the expansion of a bronchus or bronchial tubes.
Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.
Applications
DescriptionSalmeterol is a long-acting β2-adrenergic receptor agonist (β2-AR; EC50s = 0.79, 63.1, and 9.4 nM for β2-, β1-, and β3-ARs, respectively). It inhibits electrically-stimulated contraction of isolated guinea pig trachea strips (EC50 = 2.51 nM) and histamine-induced bronchoconstriction in guinea pigs via aerosol administration of doses ranging from 0.12 to 12 mM. Salmeterol binds to an exosite domain of β2-adrenergic receptors, producing a slow onset of action and prolonged activation. Formulations containing salmeterol have been used in the treatment of asthma, including exercise-induced asthma, and chronic obstructive pulmonary disease.
DescriptionSalmeterol hydroxynaphthoate is a new long-acting β2-selective adrenoceptor agonist introduced as a bronchodilator for the treatment of reversible airway obstruction in asthma and chronic bronchitis. It has bronchodilatory activity as intense and four times longerlasting than equivalent doses of salbutamol. Salmeterol hydroxynaphthoate is reported to be the first bronchodilator with significant anti-inflammatory activity and hence could complement prophylactic corticosteroid therapy.
UsesA β2-Adrenergic agonist. Structural analog of Albuterol (A514500).
UsesA -Adrenergic agonist. Structural analog of albuterol
UsesSmooth wheezing anti-inflammatory
UsesBronchodilator; Beta2-adrenoceptor agonist
Upstream & downstream products
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…